The FDA on October 11, 2023, approved BRAFTOVI® with MEKTOVI® for adult patients with metastatic Non-Small Cell Lung Cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. Both BRAFTOVI® and MEKTOVI® are products of Array BioPharma Inc., a wholly owned subsidiary of Pfizer.
Bottom Ad
Advertisement
Subscribe
